Edwards Lifesciences (NYSE:EW) Updates FY 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 2.400-2.500 for the period, compared to the consensus EPS estimate of 2.482. The company issued revenue guidance of $5.9 billion-$6.1 billion, compared to the consensus revenue estimate of $5.9 billion. Edwards Lifesciences also updated its Q3 2025 guidance to 0.540-0.60 EPS.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Citigroup reaffirmed a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Evercore ISI lifted their price target on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Finally, Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $81.00.

Edwards Lifesciences Price Performance

EW stock traded down $1.23 during trading on Thursday, hitting $75.68. The company had a trading volume of 7,464,286 shares, compared to its average volume of 4,484,617. The firm has a market capitalization of $44.39 billion, a price-to-earnings ratio of 10.81, a P/E/G ratio of 3.83 and a beta of 1.11. The business has a 50 day moving average of $76.56 and a 200 day moving average of $73.51. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $78.90. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. As a group, research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president directly owned 33,496 shares of the company's stock, valued at $2,514,879.68. The trade was a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,848 shares of company stock valued at $2,314,488. Corporate insiders own 1.29% of the company's stock.

Institutional Investors Weigh In On Edwards Lifesciences

A hedge fund recently bought a new stake in Edwards Lifesciences stock. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,587 shares of the medical research company's stock, valued at approximately $266,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.